Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9878558 | 0.87 | KDM4E (0.42) | TSHRALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL31067212 | 0.87 | LMNA (0.42) | ALDH1A1MAPTMEN1KMT2AHTT | |
| SCHEMBL18366148 | 0.87 | TP53 (0.41) | TSHRALDH1A1MAPTTP53MEN1 | |
| SCHEMBL31067236 | 0.85 | ALDH1A1 (0.41) | TSHRALDH1A1PKM | |
| SCHEMBL31067210 | 0.82 | BRD4 (0.43) | TSHRALDH1A1TP53MEN1KMT2A | |
| SCHEMBL3988360 | 0.80 | AKR1C3 (0.47) | MAPTMEN1KMT2AAKR1C3AKR1C1 | |
| SCHEMBL11704881 | 0.80 | ALDH1A1 (0.40) | TSHRALDH1A1MAPTTP53MEN1 | |
| SCHEMBL6784721 | 0.79 | L3MBTL1 (0.49) | TSHRALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL1274202 | 0.76 | SMN1; SMN2 (0.47) | ALDH1A1MAPTTP53MEN1KMT2A | |
| SCHEMBL1134463 | 0.76 | ALDH1A1 (0.53) | ALDH1A1MAPTMEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026047575-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2026-03-05 | — | — | WO | disclosed |
| EP-4673431-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | Novartis AG (CH) | 2026-01-07 | — | — | EP | disclosed |
| US-12129246-B1 | Hydroquinazoline derivatives for the treatment of a disease or disorder | NOVARTIS AG (CH) | 2024-10-29 | — | — | US | disclosed |
| US-20240336598-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-10-10 | — | — | US | disclosed |
| WO-2024180499-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2024-09-06 | — | — | WO | disclosed |
| CN-100432049-C | Cycloalkene derivatives, process for producing the same and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2008-11-12 | — | — | CN | disclosed |
| EP-1524263-A1 | prodrugs containing cycloalkene derivatives | Takeda Pharmaceutical Company Limited (JP) | 2005-04-20 | — | — | EP | disclosed |
| EP-1063228-B1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND USE | TAKEDA PHARMACEUTICAL (JP) | 2005-01-19 | — | — | EP | disclosed |
| EP-1001774-B1 | USE OF PHOSPHOLAMBAN INHIBITORS FOR INCREASING CORONARY FLOW | ORION CORP (FI) | 2004-09-15 | — | — | EP | disclosed |
| US-6774103-B1 | Compounds for deactivating phospholamban function on Ca-ATPase (phospholamban inhibitors) | ORION CORPORATION (FI) | 2004-08-10 | — | — | US | disclosed |
| US-6265421-B1 | DILATATION OF ARTERIES | ORION CORPORATION (FI) | 2001-07-24 | — | — | US | disclosed |
| CN-1291184-A | Cycloalkene derivatives, process for producing the same and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-04-11 | — | — | CN | disclosed |
| EP-1063228-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2000-12-27 | — | — | EP | disclosed |
| EP-1039884-A1 | A METHOD FOR THE PREVENTION AND TREATMENT OF STUNNED MYOCARDIUM | ORION CORPORATION (FI) | 2000-10-04 | — | — | EP | disclosed |
| EP-1017691-A1 | BISETHERS OF 1-OXA, AZA AND THIANAPHTHALEN-2-ONES AS PHOSPHOLAMBAN INHIBITORS | ORION CORPORATION (ORION-YHTYMA OY) (FI) | 2000-07-12 | — | — | EP | disclosed |
| EP-1001774-A1 | USE OF PHOSPHOLAMBAN INHIBITORS TO INCREASING CORONARY FLOW | ORION CORPORATION (FI) | 2000-05-24 | — | — | EP | disclosed |
| US-5968959-A | ADMINISTERING PHOSPHOLAMBAN INHIBITOR | ORION CORPORATION (FI) | 1999-10-19 | — | — | US | disclosed |
| WO-1999030696-A1 | A METHOD FOR THE PREVENTION AND TREATMENT OF STUNNED MYOCARDIUM | ORION CORPORATION (FI) | 1999-06-24 | — | — | WO | disclosed |
| WO-1999015523-A1 | BISETHERS OF 1-OXA, AZA AND THIANAPHTHALEN-2-ONES AS PHOSPHOLAMBAN INHIBITORS | ORION CORPORATION (FI) | 1999-04-01 | — | — | WO | disclosed |
| WO-1999000132-A1 | USE OF PHOSPHOLAMBAN INHIBITORS FOR INCREASING CORONARY FLOW | ORION CORPORATION (FI) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12129246-B1 | Hydroquinazoline derivatives for the treatment of a disease or disorder | RECQL, NRAS, RAB1A | TSHR 1301/4885ALDH1A1 810/4885MAPT 2473/4885 |
| US-20240336598-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | RECQL, NRAS, RAB1A | TSHR 1301/4885ALDH1A1 810/4885MAPT 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.